“I didn’t want to believe my disease would progress. But it did. Is there anything that can help me now?”

Consider a dose increase to GLIVEC 800 mg/day in metastatic patients with progression before exploring alternate therapies1,2

Patient characteristics

76 years old

Ileal KIT+ GIST
(metastasized)

Mitotic rate:
>5/50 HPFs

30 months since diagnosis

Original tumours:
3-9 cm

Exon 11
mutation

Patient characteristics

76 years old

Ileal KIT+ GIST
(metastasized)

Mitotic rate:
>5/50 HPFs

30 months since diagnosis

Original tumours:
3-9 cm

Exon 11
mutation

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):ii21-ii-26.